BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 25312842)

  • 1. Have the American College of Surgeons Oncology Group Z0011 trial results influenced the number of lymph nodes removed during sentinel lymph node dissection?
    Robinson KA; Pockaj BA; Wasif N; Kaufman K; Gray RJ
    Am J Surg; 2014 Dec; 208(6):1060-4; discussion 1063-4. PubMed ID: 25312842
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial on clinical management of the axilla in older breast cancer patients: a SEER-medicare analysis.
    Caretta-Weyer H; Greenberg CG; Wilke LG; Weiss J; LoConte NK; Decker M; Steffens NM; Smith MA; Neuman HB
    Ann Surg Oncol; 2013 Dec; 20(13):4145-52. PubMed ID: 23959051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The exportability of the ACOSOG Z0011 criteria for omitting axillary lymph node dissection after positive sentinel lymph node biopsy findings: a multicenter study.
    Delpech Y; Bricou A; Lousquy R; Hudry D; Jankowski C; Willecocq C; Thoury A; Loustalot C; Coutant C; Barranger E
    Ann Surg Oncol; 2013 Aug; 20(8):2556-61. PubMed ID: 23456432
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Number of lymph nodes removed in sentinel lymph node-negative breast cancer patients is significantly related to patient age and tumor size: a new source of bias in morbidity assessment?
    Port ER; Patil S; Stempel M; Morrow M; Cody HS
    Cancer; 2010 Apr; 116(8):1987-91. PubMed ID: 20151427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Size of Extranodal Extension on Sentinel Lymph Node Dissection in the American College of Surgeons Oncology Group Z0011 Trial Era.
    Choi AH; Blount S; Perez MN; Chavez de Paz CE; Rodriguez SA; Surrusco M; Garberoglio CA; Lum SS; Senthil M
    JAMA Surg; 2015 Dec; 150(12):1141-8. PubMed ID: 26331347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of the number of sentinel lymph nodes harvested with survival in breast cancer.
    Bonneau C; Bendifallah S; Reyal F; Rossi L; Rouzier R
    Eur J Surg Oncol; 2015 Jan; 41(1):52-8. PubMed ID: 25466979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial.
    Giuliano AE; Ballman KV; McCall L; Beitsch PD; Brennan MB; Kelemen PR; Ollila DW; Hansen NM; Whitworth PW; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Morrow M
    JAMA; 2017 Sep; 318(10):918-926. PubMed ID: 28898379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of the American College of Surgeons Oncology Group Z0011 Randomized Trial on the Number of Axillary Nodes Removed for Patients with Early-Stage Breast Cancer.
    Yao K; Liederbach E; Pesce C; Wang CH; Winchester DJ
    J Am Coll Surg; 2015 Jul; 221(1):71-81. PubMed ID: 25899731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery.
    Chung A; Gangi A; Mirocha J; Giuliano A
    Ann Surg Oncol; 2015 Apr; 22(4):1128-32. PubMed ID: 25300606
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measuring the impact of the American College of Surgeons Oncology Group Z0011 trial on breast cancer surgery in a community health system.
    Wright GP; Mater ME; Sobel HL; Knoll GM; Oostendorp LD; Melnik MK; Chung MH
    Am J Surg; 2015 Feb; 209(2):240-5. PubMed ID: 25236187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Do the ACOSOG Z0011 Criteria Affect the Number of Sentinel Lymph Nodes Removed?
    Subhedar P; Stempel M; Eaton A; Morrow M; Gemignani ML
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(0 3):S470-5. PubMed ID: 26178759
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evolution of axillary nodal staging in breast cancer: clinical implications of the ACOSOG Z0011 trial.
    Shah-Khan M; Boughey JC
    Cancer Control; 2012 Oct; 19(4):267-76. PubMed ID: 23037494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of the American College of Surgeons Oncology Group (ACOSOG) Z0011 trial: An institutional review.
    Le VH; Brant KN; Blackhurst DW; Schammel CM; Schammel DP; Cornett WR; McKinley BP
    Breast; 2016 Oct; 29():117-9. PubMed ID: 27479042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Which sentinel lymph-node (SLN) positive breast cancer patient needs an axillary lymph-node dissection (ALND)--ACOSOG Z0011 results and beyond.
    Gatzemeier W; Mann GB
    Breast; 2013 Jun; 22(3):211-6. PubMed ID: 23478200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Surgical complications associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011.
    Lucci A; McCall LM; Beitsch PD; Whitworth PW; Reintgen DS; Blumencranz PW; Leitch AM; Saha S; Hunt KK; Giuliano AE;
    J Clin Oncol; 2007 Aug; 25(24):3657-63. PubMed ID: 17485711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omitting axillary lymph node dissection after positive sentinel lymph node in the post-Z0011 era: Compliance with NCCN and ASCO clinical guidelines and Z0011 criteria in a large prospective cohort.
    Costaz H; Boulle D; Bertaut A; Rouffiac M; Beltjens F; Desmoulins I; Peignaux K; Ladoire S; Causeret S; Loustalot C; Padeano MM; Vincent L; Jankowski C; Arnould L; Coutant C
    Bull Cancer; 2022 Mar; 109(3):268-279. PubMed ID: 34838310
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Population-Based Study of the Effects of a Regional Guideline for Completion Axillary Lymph Node Dissection on Axillary Surgery in Patients with Breast Cancer.
    Tsao MW; Cornacchi SD; Hodgson N; Simunovic M; Thabane L; Cheng J; O'Brien MA; Strang B; Mukherjee SD; Lovrics PJ
    Ann Surg Oncol; 2016 Oct; 23(10):3354-64. PubMed ID: 27342830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which patients with sentinel node-positive breast cancer after breast conservation still receive completion axillary lymph node dissection in routine clinical practice?
    Hennigs A; Köpke M; Feißt M; Riedel F; Rezai M; Nitz U; Moderow M; Golatta M; Sohn C; Schneeweiss A; Heil J
    Breast Cancer Res Treat; 2019 Jan; 173(2):429-438. PubMed ID: 30315437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of the axilla: has Z0011 had an impact?
    Joyce DP; Lowery AJ; McGrath-Soo LB; Downey E; Kelly L; O'Donoghue GT; Barry M; Hill AD
    Ir J Med Sci; 2016 Feb; 185(1):145-9. PubMed ID: 25595827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.